Literature DB >> 20185296

Constitutive HIF-1 activity in malignant melanoma.

Silke Kuphal1, Andreas Winklmeier, Christina Warnecke, Anja-Katrin Bosserhoff.   

Abstract

The hypoxia-inducible factor-1 (HIF-1), which consists of the constitutive HIF-1beta and the oxygen-responsive HIF-1alpha subunit, is the master activator of the cellular transcriptional response to hypoxia coordinating gene expression during reduced oxygen tension. Overexpression of HIF-1 and increased transcriptional activity induced by hypoxia are linked to progression of many tumour types such as head and neck cancer, cervical carcinoma, leukaemia and renal cell carcinoma. In this study, we demonstrate that HIF activity is increased in malignant melanoma cells already under normoxic conditions in contrast to other tumour types. HIF-1alpha and -2alpha knockdown by siRNA transfection revealed that this effect is due to constitutive HIF-1alpha expression. Furthermore, the inhibition or activation of reactive oxygen species (ROS) decreased or activated, respectively, HIF-1 activity and HIF-1alpha protein expression. Interestingly, the inhibition of the NFkappaB pathway also reduced the accumulation of HIF-1alpha assuming a context between ROS and NFkappaB, and suggesting that ROS and NFkappaB activity contribute to HIF-1alpha accumulation. In summary, we identified an increased HIF-1alpha protein expression and activity in melanoma under normoxia mediated by ROS and the NFkappaB pathway. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20185296     DOI: 10.1016/j.ejca.2010.01.031

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  39 in total

Review 1.  Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Mol Aspects Med       Date:  2013-08-29

2.  A meta-analysis of HIF-1α and esophageal squamous cell carcinoma (ESCC) risk.

Authors:  Guogui Sun; Wanning Hu; Yifang Lu; Yadi Wang
Journal:  Pathol Oncol Res       Date:  2013-05-09       Impact factor: 3.201

3.  Knockdown of FBXO22 inhibits melanoma cell migration, invasion and angiogenesis via the HIF-1α/VEGF pathway.

Authors:  Yufan Zheng; Hairong Chen; Yang Zhao; Xuping Zhang; Jinjin Liu; Yu Pan; Jin Bai; Hongwei Zhang
Journal:  Invest New Drugs       Date:  2019-03-18       Impact factor: 3.850

4.  miR-33a functions as a tumor suppressor in melanoma by targeting HIF-1α.

Authors:  Jianda Zhou; Dan Xu; Huiqing Xie; Jingtian Tang; Rui Liu; Jingjing Li; Shaohua Wang; Xiang Chen; Juan Su; Xiao Zhou; Kun Xia; Quanyong He; Jia Chen; Wei Xiong; Peiguo Cao; Ke Cao
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

5.  HIF-1α acts as a molecular target for simvastatin cytotoxicity in B16.F10 melanoma cells cultured under chemically induced hypoxia.

Authors:  Emilia Licarete; Alina Sesarman; Valentin Florian Rauca; Lavinia Luput; Laura Patras; Manuela Banciu
Journal:  Oncol Lett       Date:  2017-03-27       Impact factor: 2.967

6.  Phenotypic diversity of patient-derived melanoma populations in stem cell medium.

Authors:  Malgorzata Sztiller-Sikorska; Mariusz L Hartman; Beata Talar; Justyna Jakubowska; Izabela Zalesna; Malgorzata Czyz
Journal:  Lab Invest       Date:  2015-04-13       Impact factor: 5.662

7.  The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1α expression and HIF-dependent attendant pathways.

Authors:  A Slominski; T-K Kim; A A Brożyna; Z Janjetovic; D L P Brooks; L P Schwab; C Skobowiat; W Jóźwicki; T N Seagroves
Journal:  Arch Biochem Biophys       Date:  2014-07-02       Impact factor: 4.013

8.  Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.

Authors:  Michael P O'Connell; Katie Marchbank; Marie R Webster; Alexander A Valiga; Amanpreet Kaur; Adina Vultur; Ling Li; Meenhard Herlyn; Jessie Villanueva; Qin Liu; Xiangfan Yin; Sandy Widura; Janelle Nelson; Nivia Ruiz; Tura C Camilli; Fred E Indig; Keith T Flaherty; Jennifer A Wargo; Dennie T Frederick; Zachary A Cooper; Suresh Nair; Ravi K Amaravadi; Lynn M Schuchter; Giorgos C Karakousis; Wei Xu; Xiaowei Xu; Ashani T Weeraratna
Journal:  Cancer Discov       Date:  2013-10-08       Impact factor: 39.397

9.  Effect of hypoxia factors gene silencing on ROS production and metabolic status of A375 malignant melanoma cells.

Authors:  Ivana Špaková; Miroslava Rabajdová; Helena Mičková; Wolfgang F Graier; Mária Mareková
Journal:  Sci Rep       Date:  2021-05-14       Impact factor: 4.996

10.  Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study.

Authors:  Helena Pópulo; Beatriz Domingues; Cristina Sampaio; José Manuel Lopes; Paula Soares
Journal:  J Exp Pharmacol       Date:  2021-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.